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Background: Metabolic homeostasis is central to normal cardiac function. The molecular mechanisms underlying meta-
bolic plasticity in the heart remain poorly understood.
Results: Kruppel-like factor 15 (KLF15) is a direct and independent regulator of myocardial lipid flux.
Conclusion: KLF15 is a core component of the transcriptional circuitry that governs cardiac metabolism.
Significance: This work is the first to implicate the KLF transcription factor family in cardiac metabolism.
The mammalian heart, the body’s largest energy consumer,
has evolved robust mechanisms to tightly couple fuel supply
with energy demand across a wide range of physiologic and
pathophysiologic states, yet, when compared with other organs,
relatively little is known about the molecular machinery that
directly governsmetabolic plasticity in the heart. Although pre-
vious studies have defined Kruppel-like factor 15 (KLF15) as a
transcriptional repressor of pathologic cardiac hypertrophy, a
direct role for the KLF family in cardiac metabolism has not
been previously established. We show in human heart samples
that KLF15 is induced after birth and reduced in heart failure, a
myocardial expression pattern that parallels reliance on lipid
oxidation. Isolated working heart studies and unbiased tran-
scriptomic profiling in Klf15-deficient hearts demonstrate that
KLF15isanessentialregulatoroflipidfluxandmetabolichomeo-
stasis in the adult myocardium. An important mechanism by
which KLF15 regulates its direct transcriptional targets is via
interaction with p300 and recruitment of this critical co-activa-
tor to promoters. This study establishes KLF15 as a key regula-
tor ofmyocardial lipid utilization and is the first to implicate the
KLF transcription factor family in cardiac metabolism.
The working mammalian heart requires enormous amounts
of energy to maintain contractile function and blood flow.
Under physiologic conditions, themajority this energy produc-
tion is derived from oxidative catabolism of fatty acids (FAs)3
(70%), with the remainder being derived from glucose
(20%) and other substrates, such as lactate and ketones
(10%) (1). In order to maintain contractile performance
under a wide range of physiologic and pathophysiologic set-
tings, the myocardium has evolved critical molecular mecha-
nisms that match fuel supply with energy demand and nutrient
availability (2–4).
Amajor formof the heart’smetabolic plasticity is its ability to
augment lipid utilization as a means to guard against energy
depletion and circulatory failure during periods of transient
carbohydrate deprivation (e.g. fasting) or heightened energy
needs (e.g. exercise, postnatal growth). Defects in specific genes
critical for efficient myocardial lipid utilization are known to
cause metabolic cardiomyopathies in both animal models and
humans (5). In addition, loss of metabolic plasticity has been
observed in common forms of human heart failure (5–8), a
leading cause of hospitalization and death worldwide (5).
Importantly, recent studies strongly support the contention
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that dysregulated lipid utilization and energy homeostasis play
a causal role in heart failure progression (9, 10). As recently
highlighted by Goldberg et al. (2), although the heart is far and
away the most energy-requiring organ in the body, studies of
cardiac lipid metabolism, especially in vivo are relatively scarce
comparedwith investigations in adipose tissue, liver, or skeletal
muscle. A better understanding of the fundamental mecha-
nisms governing metabolic plasticity in the myocardium may
therefore provide key insights into heart failure pathogenesis
and pave the way for novel therapeutic approaches for this
common and lethal condition.
Efficient myocardial lipid flux involves coordination of sev-
eral key enzymatic steps, including sarcolemmal FA uptake and
activation, maintenance of the intracellular triglyceride (TG)
pool, acyl-CoA import into the mitochondrial matrix, -oxida-
tion, TCAcycle, and oxidative phosphorylation (1, 2, 5, 11). The
enzymatic machinery regulating each of these steps is under
robust allosteric and transcriptional control in a manner that
tightly couples lipid flux with energy demand and nutrient
availability (12, 13). Despite the fundamental importance of
metabolic plasticity in the heart, there is surprisingly little
known about the transcriptional pathways that directly regu-
late myocardial substrate flux. When compared with the vast
body of work that has defined gene-regulatory networks gov-
erning myocyte hypertrophy (14), the identification of tran-
scription factors that are bona fide anddirect regulators ofmyo-
cardial nutrient flux is limited to a few members of the nuclear
receptor superfamily (PPARs and ERRs) and the forkhead box
factor FoxO1 (12, 15–17).
Kruppel-like factors (KLFs) are DNA-binding transcrip-
tional regulators that contain three conserved zinc fingers
within the carboxyl terminus that bind a putative consensus
5-C(A/T)CCC-3 motif in the promoters and enhancers of
various genes (18, 19). The amino terminus is involved in tran-
scriptional activation and repression as well as protein-protein
interaction. Previous studies from our group have defined
KLF15 as a transcriptional repressor of pathologic cardiac
hypertrophy (20–22). In contrast, the broad transcriptional
programs directly regulated by KLF15 in the heart remain
unknown.
Initial insights linking the KLF transcription factor family to
metabolic homeostasis were gleaned from our studies defining
KLF15 as a regulator of adipogenesis (23). Subsequent studies
in liver and skeletal muscle in the context of circadian cycles,
fasting, and exercise now identify KLF15 as a central compo-
nent of the transcriptional circuitry that regulates physiologic
flux of all three major nutrient classes (glucose, lipids, and
amino acids) (24–26). Despite these important observations,
no role for anymember of theKLF family in cardiacmetabolism
has been elucidated.
Here, we demonstrate that Kruppel-like factor 15 (KLF15) is
a direct and independent regulator of myocardial lipid flux in
vivo through a molecular mechanism involving recruitment of
the chromatin remodeling enzyme p300 to target promoters.
This study introduces an entirely new class of transcriptional
regulators (KLFs) to the core molecular circuitry that governs
myocardial metabolism.
EXPERIMENTAL PROCEDURES
Animal Models—All protocols concerning animal use were
approved by the Institutional Animal Care and Use Committee
at Case Western Reserve University and conducted in strict
accordance with theNational Institutes of Health Guide for the
Care and Use of Laboratory Animals. Klf15/mice have been
described previously (23). Studies were performed with age-
and sex-matched littermate controls (12–14 weeks old, male,
pure C57Bl/6 background). Mice were housed in a tempera-
ture- and humidity-controlled barrier facility with a 12-h light/
dark cycle and ad libitum access to water and standard labora-
tory rodent chow (Laboratory diet P3000; 4.5% fat by weight,
14% kcal).
Cell Culture—Neonatal rat ventricular myocytes (NRVM)
were isolated from 2-day-old rat pups and isolated and main-
tained under standard conditions as described previously (20,
21, 27). Isolated NRVM were cultured for 24–48 h under qui-
escent conditions by the inclusion of serum-free DMEM sup-
plemented with insulin, transferrin, and selenium prior to
experiments. C2C12 myoblasts were purchased from ATCC
(Manassas, VA) and grown in DMEM supplemented with 10%
FBS. C2C12 myoblasts were passaged prior to reaching 60%
confluence to maintain cells in the undifferentiated state. All
studies used low passage C2C12 (passages 3–6). P300/
mouse embryonic fibroblasts (28)were cultured inDMEMsup-
plemented with 10% FBS as described previously (29).
Plasmids and Adenoviruses—Expression plasmids contain-
ing the mouse KLF15 cDNA have been described previously
(20). The 1.2 kb promoter region of mouse Slc27a1 (Fatp1)
was PCR-amplified frompurified genomicDNA (Promega) and
subcloned into pGL3-basic (Promega). The Pdk4 promoter-lu-
ciferase construct was a gift from D. Kelly (30). For shRNA
against mouse/rat Klf15, the hairpin sequence 5-GCGGTAA-
GATGTACATCAAACGTGTGCTGTCCGTTTGGTGTAC-
ATCTTGCTGC-3 (loop sequence is underlined) was sub-
cloned into the pEQ adenoviral shRNA vector (Welgen, Inc.).
Recombinant adenoviruses for sh-Klf15 and sh-scrambledwere
amplified and purified by Welgen, Inc.
Isolated Working Heart—The isolated mouse working heart
perfusion was performed at the Washington University Meta-
bolic Core as described previously (31, 32). In brief, hearts were
excised and placed in ice-cold Krebs-Henseleit solution. Retro-
grade perfusion of the aortawas first performed via the Langen-
dorff method followed by left atrial cannulation. Working
mode was maintained in oxygenated buffer containing 0.4 mM
palmitate, 5.0 mM glucose, and 100 microunits insulin/ml with
a preload pressure of 11.5 mm Hg and afterload pressure of 50
mmHg. Palmitate and glucose oxidation rateswere determined
using radiolabeled [3H]palmitate and [U-14C]glucose, respec-
tively. Samples were collected every 10 min, and 3H2O and
14CO2 radioactivity was counted to determine palmitate and
glucose oxidation rates, respectively. In addition, functional
measurements such as cardiac output, peak systolic pressure,
and heart rate were measured as described previously (31).
Human Left Ventricular Samples—Human left ventricular
RNA samples were obtained as described previously (6). In
brief, myocardial specimens were collected before and after left
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ventricular assisted device (LVAD) implantation and explanta-
tion as a bridge to transplantation for end-stage HF patients.
Control heart samples were obtained fromnon-failing hearts as
described previously (6). Fetal left ventricular samples were
obtained at the time of elective termination immediately fol-
lowing tissue extraction. The use of all human samples was
approved by the Institutional Review Board of Columbia Uni-
versity andCaseWesternReserveUniversity (IRB-AAAE7393).
Measurement of Plasma Parameters and Tissue Lipids—
Hearts and plasmawere rapidly harvested and flash frozen from
WT and KOmice. Lipids were extracted from ventricles by the
Folch method. Cardiac FA and TG content was quantified by
thin layer chromatography by theNational Institutes ofHealth-
Mouse Metabolic Phenotyping Core/Lipid Analytic Core at
Vanderbilt University. Plasma free fatty acids and TGs were
quantified by the Vanderbilt National Institutes of Health
Mouse Metabolic Phenotyping Core.
Mitochondrial Physiology and Electron Microscopy—Myo-
cardia of four individual WT or KO mice were pooled for each
experiment. The data presented are from four independent
experiments. Fresh myocardial subsarcolemmal mitochondria
were isolated as described previously (33). Mitochondrial pro-
tein concentration, citrate synthase activity, and oxygen con-
sumption (using a Clark-type oxygen electrode at 30 °C) were
assayed as described previously (33, 34).Mouse heart tissuewas
freshly dissected and rapidly processed for transmission elec-
tron microscopy as described previously (35).
Mitochondrial Genome Quantification—Total tissue DNA
was prepared from hearts of WT versus KO mice using the
QIAamp DNA minikit (Qiagen) according to the manufactur-
er’s instructions. SYBR Green qPCR of purified DNA was per-
formed using primers specific for themousemitochondrialMt-
Cox2 gene. Values were normalized to the nucleus-encoded
mouse Rplp0 gene using the Ct method. Primer sequences
are available upon request.
Chromatin Immunoprecipitation—Chromatin isolated from
15 million NRVM were used for each immunoprecipitation.
NRVM were infected with empty virus or Ad-KLF15-FLAG,
fixed with 1.1% formaldehyde for 10 min, and quenched with
0.125 M glycine for 5 min. Chromatin was extracted and son-
icated using a BioRuptor (Diagnode, Sparta, NJ). The soni-
cated chromatin was immunoprecipitated with 5 g of anti-
FLAG(M2)antibodies (Sigma) bound toDynabeads (Invitrogen)
followed by extensive washing and elution. For heart tissue,
chromatin isolated from two hearts was pooled for a single
immunoprecipitation. Tissue was finely minced in PBS supple-
mented with protease inhibitors, fixed with 1.1% formaldehyde
(10 min), and quenched with 0.125 M glycine (5 min). Tissues
were disrupted using a Dounce homogenizer followed by chro-
matin extraction and sonication with a Bioruptor. Approxi-
mately 500 g of chromatin was used in each immunoprecipi-
tation with 5 g of anti-p300 antibody (C-20, Santa Cruz
Biotechnology, Inc.) bound toDynabeads followed by extensive
washing and elution. Chromatin was then reverse cross-linked
followed by purification of genomic DNA. Target and non-tar-
get regions of genomic DNA were amplified by qPCR in both
the immunoprecipitates and input samples. For NRVM sam-
ples, the rat Alb1 locus was used as a non-target control. For
mouse heart tissue samples, the 28 S genomic locus was used as
a non-target control. Relative abundance in immunoprecipi-
tates was expressed as the percentage of abundance in input sam-
ples as described previously (26, 36). ChIP primer sequences are
available upon request.
RNA Extraction and qPCR—Tissue samples were disrupted/
homogenized in PureZOLTM (Bio-Rad) in a Tissue-lyzer (Qia-
gen), using stainless steel beads (30 Hz for a total of 4 min).
Total RNA was isolated using the AurumTM (Bio-Rad) RNA
isolation kit according to the manufacturer’s directions. For
cellular samples, total RNA fromNRVMwas isolated using the
high pure RNA isolation kit (Roche Applied Science) according
to the manufacturer’s directions. For qPCR, total RNA was
deoxyribonuclease-treated on-column and transcribed to com-
plementaryDNAusing iScriptTM (Bio-Rad) following theman-
ufacturer’s protocol. qPCR was performed with the TaqMan
method (using the Roche Universal Probe Library System) on
anABI StepOne Plus real-time PCR system. Relative expression
was calculatedusing theCtmethodwithnormalization to con-
stitutive genes as indicated in each figure. Specific primer/probe
sequences are available on request.
Co-Immunoprecipitation—Co-IP was performed from
nuclear protein extracts. Nuclear protein from 293 cells or
mouse tissues was prepared using the Ne-PER kit (Pierce)
according to themanufacturer’s instructions. For each IP, 100–
200 g of nuclear protein was loaded in IP dilution buffer (50
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.2% Nonidet P-40, sup-
plemented with protease inhibitors) and immunoprecipitated
with 2–5 g of antibody bound to Dynabeads. Antibodies used
for IP were anti-Myc (9E1, Santa Cruz Biotechnology) and goat
polyclonal anti-KLF15 (Abcam). Immune complexes were
washed extensively and eluted in SDS sample buffer. Immuno-
precipitated and input proteins were run on SDS-PAGE and
immunoblotted with the following antibodies as indicated:
anti-p300 (N-15, Santa Cruz Biotechnology), anti-HA (HA-7,
Sigma), anti-Myc (9E10, Santa Cruz Biotechnology), and goat
polyclonal anti-KLF15 (Abcam). Secondary HRP-conjugated
antibodies and ECL-plus chemiluminescent detection reagent
were from Amersham Biosciences.
Microarray Analysis and Bioinformatics—Total ventricular
tissue RNA was purified from wild-type and Klf15/ mice
(n 4), which were subject to an 18-h overnight fast (4 p.m. to
10 a.m. the following morning). Labeling, hybridization, and
scanning using an Affymetrix Genechip (Mouse Genome 430A
2.0 Array) were performed at the Harvard Partners Center for
Genetics and Genomics. Raw microarray data were subject to
background subtraction and multiarray normalization. Microar-
ray data were log-transformed before differential expression
analysis using the limma package (37). Probes with a p value of
less than 0.05 after adjusting for false discovery rate using Ben-
jamini and Hochberg method (38) were considered significant
in differential expression. Enrichment in biological processes
was analyzed using the DAVID bioinformatics suite (39, 40).
The data set was submitted to the NCBI Gene Expression
Omnibus with the accession number GSE53231.
Promoter-Luciferase Studies—Transient transfections of the
indicated promoter plasmids using cultured NRVM or C2C12
cells at 70% confluence were carried out using Fugene6 (Roche
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Applied Science and Promega) following the manufacturer’s
instructions, and bioluminescence was recorded on a Veritas
luminometer (Turner Biosystems) as described previously (20,
26).
Data Analysis—All results are expressed as means, and error
bars depict S.E. Statistical analysis of microarray data is
described separately above. For experiments comparing the
means of two normally distributed groups, two-tailed Student’s
t test for unpaired data was used. Statistical significance was
defined as p 0.05.
RESULTS
KLF15 Regulates Myocardial Lipid Utilization—Because
KLF15 has been demonstrated to be important for fasting-in-
duced gluconeogenesis in the liver (24), we first assessed its
expression pattern in hearts of adult mice in the fed, fasted, and
refed states. As with previously identified metabolic regulators,
such asPdk4 and Fatp1,Klf15was robustly inducedwith fasting
with a return to baseline after refeeding (Fig. 1A), suggesting a
role in cardiac metabolic function. Klf15 expression was very
low in neonatal mouse hearts and significantly induced with
postnatal maturation in a pattern that paralleled other impor-
tant metabolic genes (Pdk4 and Fatp1) during this transition
from neonatal cardiac metabolism (glucose utilization) to that
of the adult (predominance of lipid oxidation) (7) (Fig. 1B). In a
similar manner,KLF15 expression was induced during the fetal
to adult transition in human heart tissue (Fig. 1C). Conversely,
KLF15 has been shown to be substantially down-regulated in
rodent models of heart failure (20, 21), a pathologic state where
myocardial lipid utilization is reduced (5, 6). Consistent with
this rodent data, we found KLF15 to be significantly reduced in
failing human hearts with a significant recovery of expression
after mechanical unloading with a left ventricular assist device
(Fig. 1D) (6). Although we have shown that KLF15 functions as
a transcriptional repressor of prohypertrophic signaling in car-
diomyocytes (20, 21), the gene networks directly regulated by
FIGURE1.KLF15 is regulated inphysiological andpathological conditions.A,Klf15, Ep300, Pdk4, and Fatp1 expression inmouseheart during fed, fasted (24
h), and refed (24 h of fasting followed by 24 h of refeeding). n 5. *, p 0.05 versus Fed. **, p 0.05 versus fasted. B, Klf15, Ep300, Pdk4, Fatp1,Glut4, andGlut1
expression inmouse heart during postnatal maturation (n 4). *, p 0.05 versus day 1. C, KLF15 expression in fetal versus adult human heart tissue (n 3–4).
p 0.05.D, KLF15 expression in humanhearts that are non-failing,with advancedheart failure (prior to LVADplacement), andpost-LVADplacement (n 3–4).
*, p 0.05 versus non-HF. **, p 0.05 versus Pre-LVAD. Rodent values are normalized to cyclophilin-B (Ppib) and human values to 18 S rRNA. Error bars, S.E.
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KLF15 in the myocardium remain largely unknown. Based on
the data above, we hypothesized that KLF15 might play an
important role in metabolic function of the adult heart.
To establish a tissue-intrinsic role for KLF15 in cardiac
metabolism, we performed ex vivo isolated working heart
(IWH) studies in wild-type (WT) and Klf15-deficient (KO)
hearts.We focused these IWH studies on fatty acid and glucose
utilization because these substrates are the major fuel sources
in the working mammalian heart (1). KO hearts had a striking
reduction in fatty acid oxidation with a parallel increase in glu-
cose oxidation (Fig. 2A). Importantly, there was no significant
difference in hemodynamic indices betweenKOandWThearts
during the IWHexperiments (Fig. 2B). Furthermore, KOhearts
are structurally normal and have preserved systolic function
under basal conditions (20). These results suggest that the
observed defect in lipid utilization is not occurring during a
state of severe contractile dysfunction. In addition, KOmice are
characterized by reduced intramyocardial FA and TG abun-
dance (Fig. 3A), despite elevated plasma concentration of FAs
and TGs (Fig. 3B). This observation was corroborated by elec-
tron microscopic examination, which revealed a striking pau-
city of intramyocellular lipid droplets in the hearts of KO mice
(Fig. 3C). Hence, KLF15 deficient hearts are unable to ade-
quately partition plasma lipids despite adequate delivery to the
myocardium.
To demonstrate an additional downstream defect in mito-
chondrial lipid catabolism independent of the above defect in
cytosolic lipid bioavailability, we directly assessed substrate uti-
lization inmitochondria freshly isolated from the hearts ofWT
and KO mice. We did not detect differences in mitochondrial
genome copy number in KO hearts (Fig. 3D). Concordant with
this finding, mitochondrial yield was equivalent between WT
and KO hearts, thus providing additional confirmation that
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mitochondrial quantity was unchanged (Fig. 3E). Furthermore,
WT and KO cardiac mitochondria exhibited no significant dif-
ferences in glutamate oxidation rates, reflecting unaltered func-
tion of the electron transport chain (Fig. 3F). Last, transmission
electron microscopy at the mitochondrial level revealed no
gross differences in mitochondrial ultrastructure (Fig. 3C).
However, when we directly assessedmitochondrial lipid oxida-
tion rates, we found that freshly isolatedmitochondria fromKO
hearts had a significant defect in fatty acid oxidation (Fig. 3G).
Thus, in addition to proximal abnormalities in sarcolemmal
lipid partitioning (Fig. 3, A and B), KLF15 is also critical for the
distal step of mitochondrial lipid oxidation.
To gain further insight into the broad defects in myocardial
lipid utilization seen above, we performed transcriptome-wide
gene expression profiling of KO heart tissue. These microarray
analyses showed that KO hearts have a transcriptomic signa-
ture characterized by a broad and significant reduction in genes
critical for myocardial substrate metabolism, including genes
involving lipid utilization (Fig. 4A and supplemental Table 1).
Because lipids are the dominant fuel source for the heart under
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physiologic conditions, the above transcriptomic signature and
our IWH data (Fig. 2A) prompted us to directly assess a broad
panel of lipid-related transcripts by qRT-PCR inWT versusKO
heart tissue. These analyses confirmed significant reductions in
genes encompassing nearly all major components of the myo-
cardial lipid flux pathway, including sarcolemmal FA partition-
ing/activation, intramyocellular storage, mitochondrial trans-
port and -oxidation, and peroxisomal function (Fig. 4B).
Genes directly involved in themitochondrial electron transport
chain and oxidative phosphorylation were not reduced in KO
hearts (Fig. 4C). Importantly, the observed reductions in lipid
flux targets seen in KO hearts occurred without significant
alterations in the expression of known transcriptional regula-
tors of myocellular substrate flux and energetics (Fig. 4D).
Moreover, we did not observe significant differences in key
genes involved inmyocardial glucose uptake and glycolysis (Fig.
4E) (12, 16, 41). Acute silencing as well as overexpression of
KLF15 in cultured neonatal rat cardiomyocytes significantly
reduced and augmented, respectively, expression of a parallel
panel of lipid flux targets, confirming a cell-autonomous role
for KLF15 in cardiomyocyte gene expression (Fig. 4, G and H).
KLF15 Transactivates Direct Targets via Recruitment of p300—
We next sought to establish the principle that KLF15 could
regulate key targets in this pathway via a direct mechanism of
action. Pdk4 and Fatp1 (Slc27a1) were used as exemplary tar-
gets, given the essential role of these genes in myocellular lipid
flux and extensive functional knowledge of their proximal pro-
moters (30, 42–45). The proximal promoters of both genes
were induced by KLF15 in cultured cardiomyocytes (Fig. 5A).
ChIP analysis in cardiomyocytes confirmed enrichment of
KLF15 at conservedKLF response elements on these promoters
(Fig. 5B). Thus, although Fatp1 and Pdk4 are only representa-
tive of a larger array of KLF15-regulated metabolic targets,
these focused analyses serve to establish the principle that
KLF15 can regulate important genes via direct occupancy of
target promoters.
In order to gain deeper insight into a generalizable mecha-
nism underlying KLF15-mediated target gene transactivation,
we turned to structure-function analyses.Wewere intrigued by
a recent biophysical study that demonstrated significant simi-
larity between the p300-interacting domain of p53 and a
homologous domain within the erythroid-specific KLF family
member, EKLF/KLF1 (46). Indeed, inspection of the KLF15
gene revealed a putative p300-interacting transactivation
domain (Fig. 5C) that was highly conserved from humans to
zebrafish (Fig. 5D). The possibility of cooperativity between
these two regulators on metabolic targets was further sup-
ported by our observation that myocardial Ep300 and Klf15
expression were induced in parallel during fasting and postna-
tal maturation (Fig. 1,A and B). Indeed, we observed significant
cooperativity between KLF15 and p300 upon induction of tar-
get promoters (Fig. 5E). Studies in p300/ cells revealed that
optimal target gene induction by KLF15 required endogenous
p300 (Fig. 5F). We next demonstrated interaction between
epitope-tagged KLF15 and p300when co-expressed in 293 cells
and also confirmed interaction between endogenous KLF15
and p300 in mouse heart and liver tissues (Fig. 6, A–C). Abla-
tion of theKLF15 putative p300 binding domain (KLF15p300)
abrogated the interaction with endogenous p300 (Fig. 6C)
and the cooperative induction of target promoters (Fig. 6D).
Importantly, KLF15p300 remains nucleus-localized and is
expressed as a protein of expected mobility with abundance
identical to that of identical full-length KLF15 (Fig. 6C). Finally,
ChIP against endogenous p300 inKLF15-deficientmouse heart
tissue revealed reduced p300 enrichment in the proximal pro-
moters of target genes (Fig. 6E). Taken together, the above data
establishKLF15 as a direct regulator of themyocardial lipid flux
pathway in vivo. In addition, we demonstrate that a major
mechanism of KLF15-mediated transactivation involves inter-
action with p300 and site-specific recruitment of this critical
co-activator to target promoters.
DISCUSSION
Our current findings establish KLF15 as a direct and inde-
pendent regulator of myocardial nutrient flux and thereby
introduce an entirely new class of factors (KLFs) as core com-
ponents of the transcriptional circuitry that governs cardiac
metabolism (schematized in Fig. 7). Using unbiased gene
expression profiling, we elucidate a large number of KLF15-de-
pendent targets in the heart in vivo and confirm its essential role
in regulating a transcriptional program essential for efficient
myocardial lipid flux. Furthermore, we establish a fundamental
molecular mechanism of KLF15-mediated target gene transac-
tivation, which involves its ability to interact with and recruit
the chromatin remodeling enzyme p300. Because the mamma-
lian heart’s ability tomaintain blood flow across a wide range of
physiologic and pathophysiologic circumstances depends on
tightly coupled control of fuel supply with energy demand (5),
this work suggests that KLF15 is essential for the heart’s ability
to metabolically adapt to stress. Consistent with this critical
role in myocardial adaptation, we have found that Klf15-defi-
cient mice develop dramatically accelerated heart failure after
hemodynamically (pressure overload) and neurohormonally
(chronic angiotensin II infusion) induced stress (20, 21). When
considered alongside our prior observations that implicate
KLF15 as a regulator of fasting hepatic gluconeogenesis and
skeletal muscle substrate catabolism (24–26), the current work
implicates KLF15 as a nodal integrator of nutrient flux across
diverse organ systems.
We show that cardiac KLF15, which is robustly induced dur-
ing physiologic states, such as fasting and postnatal develop-
ment, cooperates with p300 to regulate key metabolic targets.
Previous studies have implicated p300 acetyltransferase as a
positive regulator of pathologic cardiomyocyte hypertrophy,
possibly via its ability to acetylate prohypertrophic transcrip-
tion factors, such as GATA4, MEF2, and p53 (21, 47–50). Prior
work from our group has shown that Klf15 expression is dra-
matically reduced during pathologic cardiac hypertrophy, an
event that releases repression of GATA4, MEF2, and the p300-
p53 transcriptional module (20, 21). Therefore, our current
findings, when taken in the context of previously published
work, support a model in which increased levels of KLF15 (e.g.
during fasting) favor recruitment of p300 to specific metabolic
targets, whereas reduced levels of KLF15 (e.g. during pressure
overload) decrease expression of these metabolic genes and
simultaneously liberatemolecules of p300 to co-activate prohy-
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pertrophic transcription factors, such as GATA4 andMEF2. In
this manner, increased levels of KLF15 may recruit rate-limit-
ing quantities of p300 to transactivate its direct targets while
simultaneously repressing the function of p300-regulated pro-
hypertrophic transcriptional effectors.
Our IWH experiments show thatKlf15-deficient hearts have
not only a 47% reduction in palmitate oxidation but also a 32%
increase in glucose oxidation rate. These IWH data parallel
those observed in Ppara null hearts (15). Although our studies
demonstrate that KLF15, like PPAR, directly regulates genes
critical for efficient myocardial lipid utilization, there are sev-
eral potential explanations for the concomitant increase in glu-
cose oxidation rates. We did not observe increased expression
of key genes that directly participate in myocardial glucose
uptake or glycolysis (Fig. 4E). However, KO hearts did have
reduced expression of Pdk4, an important inhibitor of the pyru-
vate dehydrogenase complex. Decreased PDK4 would increase
pyruvate dehydrogenase activity, leading to increased rates of
glucose oxidation. In addition, it is possible that a primary
reduction in myocardial long chain fatty acid oxidation rates
can secondarily increase glucose oxidation rates via the well
described allosteric mechanisms of the Randle cycle (51).
Finally, it remains possible that KLF15 might regulate the
metabolism of other myocardial fuels (e.g. amino acids) in a
manner that could influence glucose homeostasis.
Because cardiac KLF15 is induced during fasting in vivo (Fig.
1A), delineation of the precise molecular events that govern its
expression will provide additional insights into its physiologic
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FIGURE 5. KLF15 directly regulates metabolic targets. A, induction of Pdk4(1.6kb)-luc and Fatp1(1.2kb)-luc in transfected NRVM (n 6). *, p 0.05. B,
ChIP against exogenously expressed KLF15 in NRVM on the proximal promoter regions of the endogenous rat Pdk4 and Fatp1 loci in the vicinity of highly
conserved KLF consensus sites (n  3). *, p  0.05. C, domain map of KLF15 protein depicting putative p300-interacting transactivation domain (residues
140–160). ZF, zinc finger. D, alignment of KLF15 protein sequence across species in the vicinity of highly conserved p300-interacting transactivation domain
(residues 140–160). E, cooperative promoter induction between KLF15 and p300 on Pdk4(1.6kb)-luc and Fatp1(1.2kb)-luc in C2C12 cells (n 5). *, p 0.05
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function. Recent studies by our group and others have identi-
fied several neurohormonal pathways as important regulators
of KLF15 expression in non-cardiac tissue. Signals known to
drive nutrient catabolism, such as glucocorticoids (52, 53) and
cAMP-response element-binding protein activation (54), have
been shown to induce KLF15 expression, whereas anabolic sig-
nals, such as insulin, can suppress its expression (55). In addi-
tion, we have recently demonstrated that cardiac KLF15
expression is directly regulated by BMAL1 (27), a central com-
ponent of themammalian circadian clock. Therefore, it is likely
that balance between such catabolic and anabolic upstream sig-
nals, with additional synchronization via the circadian clock,
regulates cardiac KLF15 function. In addition to its newly
defined role in cardiac lipid metabolism, KLF15 also regulates
the catabolism of skeletal muscle branched chain amino acids,
the body’s major store of glucogenic precursors (24, 25).
Because cardiac and skeletal muscle share similar substrate flux
machinery, it is possible that KLF15 might also regulate myo-
cardial amino acid homeostasis in a manner that influences
metabolism of other substrates and cardiac function. Given the
intense interest in the interplay between lipid and branched
chain amino acid metabolism during physiological and patho-
physiological states (56), it will be interesting to explore
whether these aspects of KLF15 function are perturbed in heart
failure and other cardiometabolic diseases.
Our current work in cardiacmetabolism is also interesting to
consider alongside our recent observation that KLF15 regulates
cardiac repolarization in vivo (27). Studies in large animalmod-
els of heart failure demonstrate that regional electromechanical
dyssynchrony is associated with profound changes in genes
critical for myocardial lipid and amino acid metabolism (57).
Because KLF15 expression has also been shown to be signifi-
cantly reduced in rodent and human heart failure (21) with
recovery of expression after mechanical unloading (Fig. 1D),
these findings collectively raise the intriguing possibility that
myocardial substrate flux and electrical activity might be sub-
ject to coordinate control by KLF15 as a form of “metabo-elec-
trical coupling.”
Previous studies have identified key members of the nuclear
receptor superfamily (e.g. PPARs and ERR) as direct regula-
tors of cardiac lipid metabolism (12, 15). We note that many of
the lipidmetabolic genes regulated by KLF15 are also known to
be PPAR targets in the heart (12). Furthermore, we find that
KLF15-deficient hearts have defects in lipid utilization as
prominent as those observed with complete PPAR deficiency
(15). Importantly, these defects in lipid metabolism and target
gene expression seen with KLF15 deficiency occur with mini-
mal alteration in expression of PPARs, ERRs, or several other
important metabolic regulators (Fig. 4D). We postulate that
KLF15 and nuclear receptors, such as PPAR, together exert
coordinated control over a subset of important shared targets.
Our observation that KLF15 binds and recruits p300 to pro-
moters supports a transactivationmodel in which KLF15 occu-
pancy favors an open chromatin configuration for the regula-
tory regions of its direct targets in the lipid flux pathway. It is
also possible that the ability of KLF15 to influence intracellular
lipid abundance may secondarily affect the bioavailability of
endogenous PPAR ligands (13). Studies exploring potential
cross-talk between KLFs and nuclear receptors in cardiac
metabolism are an area of ongoing investigation by our group.
Interestingly, KLF homologs and PPAR-like nuclear receptor
genes in C. elegans have recently been shown to both play
important roles in lipidmetabolism (58, 59), raising the intrigu-
ing possibility that coordinated control of metabolic flux by
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these two ancient transcription factor families may have been
present as early in evolution as the phylumNematoda.We specu-
late that functional interactions between KLFs and nuclear recep-
tor networks will emerge as an important theme in our under-
standing of metabolic plasticity in the myocardium as well as
across a broad range of tissues.
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